WHO ICTRP trial
Evaluation of Gamma-oryzanol in Type-2 diabetes
CTRI/2020/06/026007 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2020/06/026007 |
|---|---|
| Public title | Evaluation of Gamma-oryzanol in Type-2 diabetes |
| Scientific title | Evaluation of Efficacy and safety of Gamma-oryzanol in Type-2 diabetes: a Randomized Double Blind Placebo Controlled trial |
| Primary sponsor | AP Organics |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | India |
| Conditions | Health Condition 1: E119- Type 2 diabetes mellitus without complications |
| Interventions | Intervention1: Gamma Oryzanol Capsule: Capsule Gamma-Oryzanol (150 mg) twice daily orally along with Standard treatment for type-2 diabetes Control Intervention1: Matched Placebo: Matched Placebo twice daily orally along with Standard… |
| Registration date | Jun 22, 2020 |
| Target size | 60 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: